

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM670543

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Calysta, Inc.		08/24/2021	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	Venture Lending & Leasing IX, Inc.
Street Address:	104 La Mesa Drive, Suite 102
City:	Portola Valley
State/Country:	CALIFORNIA
Postal Code:	94028
Entity Type:	Corporation: MARYLAND

PROPERTY NUMBERS Total: 11

Property Type	Number	Word Mark
Serial Number:	85742941	BGTL
Serial Number:	85777420	BIOGTC
Serial Number:	85742938	BIOGTL
Serial Number:	86112431	BIOLOGICAL GAS TO FEED
Serial Number:	87314271	BIOLOGICAL GAS TO FEED
Serial Number:	86112432	BIOLOGICAL GAS TO FUEL
Serial Number:	85777418	BIOLOGICAL GAS-TO-CHEMICALS
Serial Number:	85742937	BIOLOGICAL GAS-TO-LIQUIDS
Serial Number:	86184784	CALYSTA
Serial Number:	85742936	CALYSTA ENERGY
Serial Number:	86591860	FEEDKIND

CORRESPONDENCE DATA

Fax Number: 4157774961

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4159811400

Email: nsust@foxrothschild.com

Correspondent Name: Jeff Klugman

Address Line 1: 1 Front Street Suite 3200

Address Line 4: San Francisco, CALIFORNIA 94111

TRADEMARK

NAME OF SUBMITTER:	Jeffrey T. Klugman
SIGNATURE:	/Jeffrey T. Klugman/
DATE SIGNED:	08/26/2021

Total Attachments: 27

source=Calysta - IP Security Agreement (executed)#page1.tif
source=Calysta - IP Security Agreement (executed)#page2.tif
source=Calysta - IP Security Agreement (executed)#page3.tif
source=Calysta - IP Security Agreement (executed)#page4.tif
source=Calysta - IP Security Agreement (executed)#page5.tif
source=Calysta - IP Security Agreement (executed)#page6.tif
source=Calysta - IP Security Agreement (executed)#page7.tif
source=Calysta - IP Security Agreement (executed)#page8.tif
source=Calysta - IP Security Agreement (executed)#page9.tif
source=Calysta - IP Security Agreement (executed)#page10.tif
source=Calysta - IP Security Agreement (executed)#page11.tif
source=Calysta - IP Security Agreement (executed)#page12.tif
source=Calysta - IP Security Agreement (executed)#page13.tif
source=Calysta - IP Security Agreement (executed)#page14.tif
source=Calysta - IP Security Agreement (executed)#page15.tif
source=Calysta - IP Security Agreement (executed)#page16.tif
source=Calysta - IP Security Agreement (executed)#page17.tif
source=Calysta - IP Security Agreement (executed)#page18.tif
source=Calysta - IP Security Agreement (executed)#page19.tif
source=Calysta - IP Security Agreement (executed)#page20.tif
source=Calysta - IP Security Agreement (executed)#page21.tif
source=Calysta - IP Security Agreement (executed)#page22.tif
source=Calysta - IP Security Agreement (executed)#page23.tif
source=Calysta - IP Security Agreement (executed)#page24.tif
source=Calysta - IP Security Agreement (executed)#page25.tif
source=Calysta - IP Security Agreement (executed)#page26.tif
source=Calysta - IP Security Agreement (executed)#page27.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is made as of August 24, 2021, between CALYSTA, INC., a Delaware corporation ("Grantor"), and VENTURE LENDING & LEASING IX, INC., a Maryland corporation ("Secured Party").

RECITALS

A. Pursuant to that certain Loan and Security Agreement and that certain Supplement to the Loan and Security Agreement, both dated as of even date herewith between Grantor, as borrower, and Secured Party, as lender (as amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement" and the "Supplement," respectively), Secured Party has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in the Loan Agreement and Supplement. All capitalized terms used herein without definition shall have the meanings ascribed to them in the Loan Agreement.

B. Secured Party is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Secured Party a security interest in the Collateral. To that end, Grantor has executed in favor of Secured Party the Loan Agreement granting a security interest in all Collateral, and is executing this Agreement with respect to certain items of Intellectual Property, in particular.

NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

1. Grant of Security Interest. As collateral security for the prompt and complete payment and performance of all of Grantor's present or future Obligations, Grantor hereby grants a security interest to Secured Party, as security, in and to Grantor's entire right, title and interest in, to and under the following Intellectual Property, now owned or hereafter acquired by Grantor or in which Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the "Collateral" for purposes of this Agreement):

(a) Any and all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or of any other country; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State thereof or any other country; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) All letters patent of, or rights corresponding thereto in, the United States or any other country, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; all reissues, continuations, continuations-in-part or extensions thereof; all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");

(c) All trademarks, trade names, corporate names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or any political subdivision thereof, and reissues, extensions or renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(d) Any and all claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(e) All licenses or other rights to use any of the Copyrights, Patents or Trademarks, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(f) All amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents;
and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding the foregoing the term "Collateral" shall not include: (a) "intent-to-use" trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such "intent to use" trademarks would be contrary to applicable law or (b) any contract, instrument or chattel paper in which Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the UCC, as applicable and as then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code or principles of equity); provided further that immediately upon the ineffectiveness, lapse or termination of any such provision, the term "Collateral" shall include, and Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party's unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and other proceeds of such contract, instrument or chattel paper.

2. Covenants and Warranties. Grantor represents, warrants, covenants and agrees as follows:

(a) Grantor has rights (as defined in the UCC) in the Collateral, except for Permitted Liens;

(b) During the term of this Agreement, Grantor will not transfer or otherwise encumber any interest in the Collateral, except for Permitted Liens and except for transfers otherwise permitted under the Loan Agreement;

(c) To its knowledge, each of the Patents is valid and enforceable, and no part of the Collateral has been judged invalid or unenforceable, in whole or in part, and no claim has been made that any part of the Collateral violates the rights of any third party;

(d) **Grantor shall deliver to Secured Party, within thirty (30) days of receiving a written request thereof (but in any event not more than once per fiscal year), a report signed by Grantor, in form reasonably acceptable to Secured Party, listing (i) any applications or registrations that Grantor has made or filed in respect of any patents, copyrights or trademarks, (ii) the status of any outstanding applications or registrations and (iii) any material change in the composition of the Collateral;**

(e) Grantor shall use reasonable commercial efforts to (i) protect, defend and maintain the validity and enforceability of the Trademarks, Patents and Copyrights material to Grantor's business, (ii) detect infringements of the Trademarks, Patents and Copyrights and promptly advise Secured Party in writing of material infringements detected, and (iii) not allow any material Trademarks, Patents or Copyrights to be abandoned, forfeited or dedicated to the public unless Grantor deems it to be in the best interest of Grantor's business;

(f) Grantor shall apply for registration (to the extent not already registered) with the United States Patent and Trademark Office or the United States Copyright Office, as applicable: (i) those intellectual property rights listed on Exhibits A, B and C hereto within thirty (30) days of the date of this Agreement; and (ii) those additional intellectual property rights developed or acquired by Grantor from time to time in connection with any product or service, prior to the sale or licensing of such product or the rendering of such service to any third party (including without limitation revisions or additions to the intellectual property rights listed on such Exhibits A, B and C), except, in each case, with respect to such rights that Grantor determines in its sole but reasonable commercial judgment need not be registered to protect its own business interests. Grantor shall, from time to time, execute and file such other instruments, and take such further actions as Secured Party may reasonably request from time to time to perfect or continue the perfection of Secured Party's interest in the Collateral; and

(g) Grantor shall not enter into any agreement that would materially impair or conflict with Grantor's obligations hereunder without Secured Party's prior written consent, which consent shall not be unreasonably withheld or delayed. Grantor shall not permit the inclusion in any material contract to which it becomes a party of any provisions that could or might in any way prevent the creation of a security interest in Grantor's rights and interests in any property included within the definition of the Collateral (other than Permitted Liens) acquired under such contracts, except for provisions in such material contracts as are referenced in the last paragraph of Section 1 of this Agreement.

3. Further Assurances: Attorney in Fact.

(a) On a continuing basis, Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and Trademark Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by Secured Party, to perfect Secured Party's security interest in all Copyrights, Patents and Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all Collateral.

(b) Grantor hereby irrevocably appoints Secured Party as Grantor's attorney-in-fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time in Secured Party's reasonable discretion, to take any reasonable action and to execute any instrument which Secured Party may deem reasonably necessary or advisable to accomplish the purposes of this Agreement, including (i) to modify, in its reasonable discretion, this Agreement without first obtaining Grantor's approval of or signature to such modification by amending Exhibits A, B and C, hereof, as appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or Trademarks in which Grantor no longer has or claims any right, title or interest, (ii) to file, in its reasonable discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Grantor where permitted by law, and (iii) after the occurrence and during the continuance of an Event of Default, to transfer the Collateral into the name of Secured Party or a third party to the extent permitted under the California Uniform Commercial Code.

(c) Secured Party agrees that upon the payment in full of the Obligations (other than inchoate indemnity obligations), the security interests granted hereby shall terminate automatically and all rights to the Collateral shall revert to Grantor. Upon any such termination, Secured Party shall, at the Grantor's expense, promptly

execute and deliver to the Grantor such documents as the Grantor shall reasonably request to evidence such termination.

4. Events of Default. The occurrence of any of the following shall constitute an Event of Default under this Agreement:

(a) An Event of Default under the Loan Agreement; or

(b) Grantor materially breaches any warranty or agreement made by Grantor in this Agreement and, as to any breach that is capable of cure, Grantor fails to cure such breach within thirty (30) days of the sooner to occur of Grantor's receipt of notice of such breach from Secured Party or the date on which such breach first becomes known to Grantor.

5. Amendments. This Agreement may be amended only by a written instrument signed by both parties hereto, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.

6. Counterparts: Electronic Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. This Agreement may be executed by electronic signatures. Grantor and Secured Party expressly agree to conduct the transactions contemplated by this Agreement by electronic means (including, without limitation, with respect to the execution, delivery, storage and transfer of this Agreement by electronic means and to the enforceability of electronic Loan Documents). Delivery of an executed signature page to this Agreement by facsimile or other electronic mail transmission shall be effective as delivery of a manually executed counterpart hereof.

[Signature Pages Follow]

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

GRANTOR:

CALYPSO, INC.
By: Alan Shaw
Name: Alan Shaw
Title: President

Address for Notices:

1900 Alameda de las Pulgas, Suite 200
San Mateo, CA 94403
Attn:
Fax #:
Phone #:

SECURED PARTY:

VENTURE LENDING & LEASING IX, INC.

By: _____
Name: _____
Title: _____

Address for Notices:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer
Fax # 650-234-4343
Phone # 650-234-4300

[Signature page to Intellectual Property Security Agreement]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

GRANTOR:

CALYSTA, INC.

By: _____
Name: _____
Title: _____

Address for Notices:

1900 Alameda de las Pulgas, Suite 200
San Mateo, CA 94403
Attn:
Fax #:
Phone #:

SECURED PARTY:

VENTURE LENDING & LEASING IX, INC.

Maurice Werdegar
By: Maurice Werdegar (Aug 17, 2007 10:03 PM) _____
Name: Maurice Werdegar
Title: Chief Executive Officer

Address for Notices:

104 La Mesa Dr., Suite 102
Portola Valley, CA 94028
Attn: Chief Financial Officer
Fax # 650-234-4343
Phone # 650-234-4300

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
402us110	US (Provisional)	Engineering Multi-Carbon Substrate Utilization Pathways in Methanotrophic Bacteria	Lapsed	24-Oct-2012	61/718,024	N/A	Calysta
402us210	US	Engineering Multi-Carbon Substrate Utilization Pathways in Methanotrophic Bacteria	Issued	24-Apr-2015	14/438,537	US 9,845,474 US 2015/0275219	Calysta
402us211d	US (DIV)	Engineering Multi-Carbon Substrate Utilization Pathways in Methanotrophic Bacteria	Issued	22-Nov-2017	15/821,510	US 10,190,123 US 2018/0112224	Calysta
402us212d	US (DIV)	Engineering Multi-Carbon Substrate Utilization Pathways in Methanotrophic Bacteria	Issued	06-Dec-2017	15/833,890	US 10,011,840 US 2018/0087059	Calysta
402wo210	PCT	Engineering Multi-Carbon Substrate Utilization Pathways in Methanotrophic Bacteria	Nat'l Phase	24-Oct-2013	PCT/US2013/066665	WO 2014/066670	Calysta
403us110	US (Provisional)	Propylene Synthesis Using Engineered Enzymes	Lapsed	18-Sep-2012	61/702,534	N/A	Calysta
403us210	US	Propylene Synthesis Using Engineered Enzymes	Issued	18-Sep-2013	US 14/429,327	US 9,816,111 US 2015/0232886	Calysta
403us211c	US (CON)	Propylene Synthesis Using Engineered Enzymes	Pending	29-Jun-2017	US 15/637,838	US 2017/0306358	Calysta
403wo210	PCT	Propylene Synthesis Using Engineered Enzymes	Nat'l Phase	18-Sep-2013	PCT/US2013/060460	WO 2014/047209	Calysta
404us110	US (Provisional)	Biorefinery System, Methods and Compositions Thereof	Lapsed	13-Jul-2012	61/671,542	N/A	Calysta
404us210	US	Biorefinery System, Methods and Compositions Thereof	Lapsed	12-Jul-2013	13/940,861	US 2014/0024872	Calysta
404us211d	US (DIV)	Biorefinery System, Methods and Compositions Thereof	Issued	19-Oct-2015	14/886,983	US 9,970,032 US 2016/0040198	Calysta
404us310	US	Biorefinery System, Methods and Compositions Thereof	Issued	12-Jul-2013	13/941,027	US 9,371,549 US 2014/0013658	Calysta
404us311d	US (DIV)	Biorefinery System, Methods and Compositions Thereof	Lapsed	27-Mar-2015	14/670,740	US 2015/0218508	Calysta
404us312c	US (CON)	Biorefinery System, Methods and Compositions Thereof	Issued	30-Jul-2015	14/813,804	US 9,410,168 US 2015/0353971	Calysta
404us313c	US (CON)	Biorefinery System, Methods and Compositions Thereof	Lapsed	20-Jun-2016	15/187,492	US 2016/0289714	Calysta
404us314c	US (CON)	Biorefinery System, Methods and Compositions Thereof	Pending	20-Jun-2016	15/187,509	US 2016/0289782	Calysta
404us315c	US (CON)	Biorefinery System, Methods and Compositions Thereof	Pending	29-Jan-2018	15/882,393	US 2018/0251800	Calysta
404wo310	PCT	Biorefinery System, Methods and Compositions Thereof	Nat'l Phase	12-Jul-2013	PCT/2013/050369	WO 2014/012205	Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
404ae310	AE	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	1471/2014		Calysta
404ae311	AE (DIV)	Biorefinery System, Methods and Compositions Thereof	Pending	07-Jun-2018	P6000764/2018		Calysta
404au310	AU	Biorefinery System, Methods and Compositions Thereof	Granted	12-Jul-2013	2013289943	2013289943	Calysta
404au311	AU (DIV)	Biorefinery System, Methods and Compositions Thereof	Lapsed	12-Jul-2013	2013289943		Calysta
404br310	BR	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	BR1120150006710		Calysta
404ca310	CA	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	2,876,509		Calysta
404cn310	CN	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	2013800370197	CN104685060A	Calysta
404ep310	EP	Biorefinery System, Methods and Compositions Thereof	Granted	12-Jul-2013	1381740.0	EP 2 872 641 B1	Calysta
404ep310	DK	Biorefinery System, Methods and Compositions Thereof	Granted	12-Jul-2013	1381740.0	DK 2 872 641	Calysta
404ep310	DE	Biorefinery System, Methods and Compositions Thereof	Granted	12-Jul-2013	1381740.0	602013035167.8	Calysta
404ep310	FR	Biorefinery System, Methods and Compositions Thereof	Granted	12-Jul-2013	1381740.0	FR 2 872 641	Calysta
404ep310	GB	Biorefinery System, Methods and Compositions Thereof	Granted	12-Jul-2013	1381740.0	GB 2 872 641	Calysta
404ep310	NL	Biorefinery System, Methods and Compositions Thereof	Granted	12-Jul-2013	1381740.0	NL 2 872 641	Calysta
404ep310	NO	Biorefinery System, Methods and Compositions Thereof	Granted	12-Jul-2013	1381740.0	NO 2 872 641	Calysta
404ep311	EP (DIV)	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	17189086.6	EP 3 305 907	Calysta
404in310	IN	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	919/DELNP/2015		Calysta
404jp310	JP	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	2015-521864	JP 2015-527883	Calysta
404jp311	JP (DIV)	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	2018-208190	JP 2019-13258	Calysta
404kr310	KR	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	10-2015-7003496		Calysta
404my310	MY	Biorefinery System, Methods and Compositions Thereof	Allowed	12-Jul-2013	PI 2015000046		Calysta
404qa310	QA	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	QA/201501/0004		Calysta
404ru310	RU	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	2014151417		Calysta
404za310	ZA	Biorefinery System, Methods and Compositions Thereof	Pending	12-Jul-2013	2014/09534		Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
406us110	US (Provisional)	Compositions and Methods for Herbicide Resistance	Lapsed	13-Dec-2012	61/736,957	N/A	Calysta
406wo210	PCT	Compositions and Methods for Herbicide Resistance	Lapsed	12-Dec-2013	PCT/US2013/074675	WO 2014/093626	Calysta
407us110	US (Provisional)	Gas-Fed Fermentation Systems	Lapsed	08-Oct-2012	61/711,104	N/A	Calysta
407us210	US	Gas-Fed Fermentation Systems	Pending	08-Apr-2015	14/434,315	US 2015/0259639	Calysta
407us211c	US (CON)	Gas-Fed Fermentation Systems	Pending	30-Jun-2017	15/639,120	US 2017/0298315	Calysta
407wo210	PCT	Gas-Fed Fermentation Systems	Nat'l Phase	07-Oct-2013	PCT/US2013/063650	WO 2014/058761	Calysta
407ae310	AE	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	445/2015		Calysta
407au310	AU	Gas-Fed Fermentation Systems	Granted	07-Oct-2013	2013329566	2013329566	Calysta
407br310	BR	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	BR1120150076386		Calysta
407ca310	CA	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	2,885,803		Calysta
407cn310	CN	Gas-Fed Fermentation Systems	Granted	07-Oct-2013	2013800566662	ZL2013800566662 / CN104781387	Calysta
407ep310	EP	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	13844924.4	EP 2904088	Calysta
407id310	ID	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	P00201502640		Calysta
407in310	IN	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	3516/DELNP/2015		Calysta
407jp310	JP	Gas-Fed Fermentation Systems	Granted	07-Oct-2013	2015-535863	JP 6487235 / JP 2015-535692	Calysta
407kr310	KR	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	10-2015-7011198		Calysta
407my310	MY	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	PI 2015000882		Calysta
407qa310	QA	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	QA/201504/00129		Calysta
407ru310	RU	Gas-Fed Fermentation Systems	Granted	07-Oct-2013	2015109899	2639542	Calysta
407za310	ZA	Gas-Fed Fermentation Systems	Pending	07-Oct-2013	2015/02057		Calysta
408us110	US (Provisional)	Genetically Engineered Microorganisms for Biological Oxidation of Hydrocarbons	Lapsed	15-Oct-2012	61/714,123	N/A	Calysta
408us210	US	Genetically Engineered Microorganisms for Biological Oxidation of Hydrocarbons	Pending	14-Apr-2015	14/435,714	US 2015/0232888	Calysta
408wo210	PCT	Genetically Engineered Microorganisms for Biological Oxidation of Hydrocarbons	Nat'l Phase	15-Oct-2013	PCT/US2013/065087	WO 2014/062703	Calysta
408cn210	CN	Genetically Engineered Microorganisms for Biological Oxidation of Hydrocarbons	Pending	15-Oct-2013	2013800535823	CN104822824	Calysta
410us110	US (Provisional)	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Lapsed	09-Nov-2012	61/724,733	N/A	Calysta
410us210	US	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Issued	06-May-2015	14/441,153	US 9,909,153 / US 2015/0299745	Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
410us21c	US (CON)	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Issued	06-May-2015	15/877,747	US 10,113,188 / US 2018/0282769	Calysta
410wo210	PCT	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Nat'l Phase	08-Nov-2013	PCT/US2013/069252	WO 2014/074886	Calysta
410ae210	AE	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	572/2015		Calysta
410au210	AU	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Granted	08-Nov-2013	2013342143	2013342143	Calysta
410br210	BR	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	BR1120150101984		Calysta
410ca210	CA	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	2,886,642		Calysta
410cn210	CN	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	2013800566639	CN104781411	Calysta
410ep210	EP	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Allowed	08-Nov-2013	13853782.4	EP 2917358	Calysta
410id210	ID	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	P00201503286		Calysta
410in210	IN	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	4944/DELNP/2015		Calysta
410jp210	JP	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Lapsed	08-Nov-2013	2015-541944		Calysta
410kr210	KR	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	10-2015-7011199		Calysta
410my210	MY	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	PI 2015001211		Calysta
410qa210	QA	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	QA/201504/00138		Calysta
410ru210	RU	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	2015109898		Calysta
410za210	ZA	Compositions and Methods for Biological Production of Fatty Acid Derivatives	Pending	08-Nov-2013	2015/02333		Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
411us110	US (Provisional)	Compositions and Methods for Biological Production of Isoprene	Lapsed	07-Mar-2013	61/774,342	N/A	Calysta
411us210	US (Provisional)	Compositions and Methods for Biological Production of Isoprene	Lapsed	16-Jan-2014	61/928,333	N/A	Calysta
411us310	US	Compositions and Methods for Biological Production of Isoprene	Lapsed	04-Sep-2015	14/773,118	US 2016/0017374	Calysta
411wo310	PCT	Compositions and Methods for Biological Production of Isoprene	Nat'l Phase	06-Mar-2014	PCT/US2014/021258	WO 2014/138419	Calysta
411ae310	AE	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	1069/2015		Calysta
411au310	AU	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	2014225631		Calysta
411br310	BR	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	BR 1120150210031		Calysta
411ca310	CA	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	2,901,588		Calysta
411cn310	CN	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	2014800123264	CN105008514	Calysta
411ep310	EP	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	14760094.4	EP 2964748	Calysta
411id310	ID	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	P000201506285		Calysta
411in310	IN	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	7537/DELNP/2105		Calysta
411jp310	JP	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	2015-561662	JP 2016-508737	Calysta
411kr310	KR	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	10-2015-7023131		Calysta
411my310	MY	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	PI 2105002190		Calysta
411qa310	QA	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	QA/201508/00346		Calysta
411ru310	RU	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	2015131480		Calysta
411za310	ZA	Compositions and Methods for Biological Production of Isoprene	Lapsed	06-Mar-2014	2015/05616		Calysta
412us110	US (Provisional)	Compositions and Methods for Recovery of Stranded Gas	Lapsed	16-Jan-2014	61/928,349	N/A	Calysta
412us210	US	Compositions and Methods for Recovery of Stranded Gas	Allowed	14-Jul-2016	15/111,723	US 2016/0333307	Calysta
412us211c	US	Compositions and Methods for Recovery of Stranded Gas	Pending	12-Mar-2019	16/299,772		Calysta
412wo210	PCT	Compositions and Methods for Recovery of Stranded Gas	Nat'l Phase	16-Jan-2015	PCT/US2015/011806	WO 2015/109221	Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
412ca210	CA	Compositions and Methods for Recovery of Stranded Gas	Pending	16-Jan-2015	2,936,848		Calysta
412ru210	RU	Compositions and Methods for Recovery of Stranded Gas	Pending	16-Jan-2015	2016133400		Calysta
413us110	US (Provisional)	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Lapsed	18-Jun-2014	62/014,007	N/A	Calysta
413us210	US	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Pending	15-Dec-2016	15/319,312	US 2017/0121718	Calysta
413wo210	PCT	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Pending	18-Jun-2015	PCT/US2015/011806	WO 2015/195972	Calysta
413au210	AU	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Pending	18-Jun-2015	2015276994		Calysta
413ca210	CA	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Pending	18-Jun-2015	2,950,304		Calysta
413ep210	EP	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Granted	18-Jun-2015	15809220.5	EP 3158065	Calysta
413de210	DE	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Granted	18-Jun-2015	15809220.5	602015023370.0	Calysta
413dk210	DK	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Granted	18-Jun-2015	15809220.5	DK 3158065	Calysta
413fr210	FR	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Granted	18-Jun-2015	15809220.5	FR 3158065	Calysta
413g2b10	GB	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Granted	18-Jun-2015	15809220.5	GB 3158065	Calysta
413nl210	NL	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Granted	18-Jun-2015	15809220.5	NL 3158065	Calysta
413no210	NO	Nucleic Acids and Vectors for Use with Methanotrophic Bacteria	Granted	18-Jun-2015	15809220.5	NO 3158065	Calysta
414us110	US (Provisional)	Compositions and Methods for Biological Production of Lactate and Derivatives Thereof	Lapsed	18-Jun-2013	61/836,609	N/A	Calysta
414us210	US (Provisional)	Compositions and Methods for Biological Production of Lactate and Derivatives Thereof	Lapsed	16-Jan-2014	61/928,390	N/A	Calysta
414us310	US	Compositions and Methods for Biological Production of Lactate	Pending	18-Dec-2015	14/898,948	US 2016/0369246	Calysta
414wo310	PCT	Compositions and Methods for Biological Production of Lactate	Nat'l Phase	18-Jun-2014	PCT/US2014/043053	WO 2014/205146	Calysta
414ae310	AE	Compositions and Methods for Biological Production of Lactate	Pending	18-Jun-2014	1695/2015		Calysta
414ca310	CA	Compositions and Methods for Biological Production of Lactate	Pending	18-Jun-2014	2,914,641		Calysta
414cn310	CN	Compositions and Methods for Biological Production of Lactate	Pending	18-Jun-2014	2014800347848	CN105378077	Calysta
414ep310	EP	Compositions and Methods for Biological Production of Lactate	Pending	18-Jun-2014	14737468.0	EP 3011017	Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
414kr310	KR	Compositions and Methods for Biological Production of Lactate	Pending	18-Jun-2014	10-2015-7036026		Calysta
414my310	MY	Compositions and Methods for Biological Production of Lactate	Pending	18-Jun-2014	PI 2015002969		Calysta
414qa310	QA	Compositions and Methods for Biological Production of Lactate	Pending	18-Jun-2014	QA/201512/00542		Calysta
414ru310	RU	Compositions and Methods for Biological Production of Lactate	Pending	18-Jun-2014	2015151210		Calysta
415us110	US (Provisional)	Amino Acid-Enriched Feed Compositions and Related Methods	Lapsed	16-Jan-14	61/928,401	N/A	Calysta
415us210	US	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	14/599,383	US 2015/0197779	Calysta
415wo210	PCT	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Nat'l Phase	16-Jan-2015	PCT/US2015/11872	WO 2015/109265	Calysta
415ae210	AE	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	P6000037/2016		Calysta
415au210	AU	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	2015206272		Calysta
415ca210	CA	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	2,936,853		Calysta
415cn210	CN	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	2015800090871	CN 106029870	Calysta
415ep210	EP	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	15737349.9	EP 3094718	Calysta
415id210	ID	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	P00201605351		Calysta
415jp210	JP	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	2016-546817		Calysta
415my210	MY	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	PI2016001304		Calysta
415qa210	QA	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Pending	16-Jan-2015	201607/00304		Calysta
415ru210	RU	Microorganisms for the Enhanced Production of Amino Acids and Related Methods	Allowed	16-Jan-2015	2016133407		Calysta
416us110	US (Provisional)	Carbohydrate-Enriched Feed Compositions and Related Methods	Lapsed	16-Jan-2014	61/928,366	N/A	Calysta
416us210	US	Carbohydrate-Enriched Recombinant Microorganisms	Allowed	14-Jul-2016	15/111,733	US 2016/0289782	Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
416wo210	PCT	Carbohydrate-Enriched Recombinant Microorganisms	Nat'l Phase	16-Jan-2014	PCT/US2015/11860	WO 2015/109257	Calysta
416ae210	AE	Carbohydrate-Enriched Recombinant Microorganisms	Pending	16-Jan-2014	P6000036/2016		Calysta
416au210	AU	Carbohydrate-Enriched Recombinant Microorganisms	Pending	16-Jan-2014	2015206264		Calysta
416br210	BR	Carbohydrate-Enriched Recombinant Microorganisms	Lapsed	16-Jan-2014	1120160165390		Calysta
416ca210	CA	Carbohydrate-Enriched Recombinant Microorganisms	Pending	16-Jan-2014	2,936,850		Calysta
416CN210	CN	Carbohydrate-Enriched Recombinant Microorganisms	Pending	16-Jan-2014	2015800047960	CN105916976	Calysta
416ep210	EP	Carbohydrate-Enriched Recombinant Microorganisms	Pending	16-Jan-2014	15737403.4	EP 3 097 185	Calysta
416id210	ID	Carbohydrate-Enriched Recombinant Microorganisms	Lapsed	16-Jan-2014	P00201605388		Calysta
416in210	IN	Carbohydrate-Enriched Recombinant Microorganisms	Lapsed	16-Jan-2014	201617026926		Calysta
416jp210	JP	Carbohydrate-Enriched Recombinant Microorganisms	Lapsed	16-Jan-2014	2016-546818	JP 2017-504330	Calysta
416kr210	KR	Carbohydrate-Enriched Recombinant Microorganisms	Pending	16-Jan-2014	10-2016-7019710		Calysta
416my210	MY	Carbohydrate-Enriched Recombinant Microorganisms	Pending	16-Jan-2014	PI2016001299		Calysta
416qa210	QA	Carbohydrate-Enriched Recombinant Microorganisms	Pending	16-Jan-2014	201607/00303		Calysta
416ru210	RU	Carbohydrate-Enriched Recombinant Microorganisms	Lapsed	16-Jan-2014	2016129316		Calysta
416za210	ZA	Carbohydrate-Enriched Recombinant Microorganisms	Lapsed	16-Jan-2014	2016/05140		Calysta
417us110	US (Provisional)	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Lapsed	15-May-2014	61/994,042	N/A	Calysta
417us210	US	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-Nov-2016	15/311,080	US 2017/0211102	Calysta
417wo210	PCT	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Nat'l Phase	14-May-2015	PCT/US2015/030836	WO 2015/175809	Calysta
417ae210	AE	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	P6000291/2016		Calysta
417au210	AU	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Granted	14-May-2015	2015259096	2015259096	Calysta
417br210	BR	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	BR 11 2016 026562 9		Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
417ca210	CA	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	2,946,846		Calysta
417cn210	CN	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	201580033257.X	CN 106574280A	Calysta
417ep210	EP	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	15726809.5	EP 3143150	Calysta
417id210	ID	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	P00201607809		Calysta
417in210	IN	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	201617041561		Calysta
417jp210	JP	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	2016-567525	JP 2017-515480	Calysta
417kr210	KR	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	10-2016-7034547		Calysta
417my210	MY	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	PI 2016001973		Calysta
417qa210	QA	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	QA/201611/00487		Calysta
417ru210	RU	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	2016145054		Calysta
417za210	ZA	Compositions and Methods for Biological Production of Very Long Carbon Chain Compounds	Pending	14-May-2015	2016/07838		Calysta
418us110	US (Provisional)	Host Cells and Method for Making Acrylate and Precursors Thereof Using an Odd Numbered Alkane Feedstock	Lapsed	19-Oct-2011	61/549,133	N/A	Calysta
418us210	US	Host Cells and Method for Making Acrylate and Precursors Thereof Using an Odd Numbered Alkane Feedstock	Issued	13-Mar-2014	14/344,899	US 9,657,317 / US 2015/0087036	Calysta
418us211c	US (CON)	Host Cells and Method for Making Acrylate and Precursors Thereof Using an Odd Numbered Alkane Feedstock	Lapsed	16-May-2017	15/597,000		Calysta
418wo210	PCT	Host Cells and Method for Making Acrylate and Precursors Thereof Using an Odd Numbered Alkane Feedstock	Nat'l Phase	17-Oct-2012	PCT/US2012/060671	WO 2013/059362	Calysta
419us110	US (Provisional)	Multiphase Porous Flow Reactors and Methods of Using Same	Lapsed	14-Nov-2011	61/559,277	N/A	Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
419us210	US (Provisional)	Multiphase Porous Flow Reactors and Methods of Using Same	Lapsed	19-Feb-2012	61/600,661	N/A	Calysta
419us310	US	Multiphase Porous Flow Reactors and Methods of Using Same	Issued	12-May-2014	14/357,767	US 9,744,515 US 2014/0323694	Calysta
419wo310	PCT	Multiphase Porous Flow Reactors and Methods of Using Same	Nat'l Phase	13-Nov-2012	PCT/US2012/064896	WO2013/074551	Calysta
420us110	US (Provisional)	Proline Auxotrophs	Lapsed	13-May-2015	62/160,896	N/A	Calysta
420us210	US	Proline Auxotrophs	Pending	13-Nov-2017	15/573,685	US 2018/0105791	Calysta
420wo210	PCT	Proline Auxotrophs	Nat'l Phase	13-May-2016	PCT/US2016/032297	WO 2016/183413	Calysta
420au210	AU	Proline Auxotrophs	Pending	13-May-2016	2016260332		Calysta
420ca210	CA	Proline Auxotrophs	Pending	13-May-2016	2,984,135		Calysta
420ep210	EP	Proline Auxotrophs	Pending	13-May-2016	16725321.0	EP 3294758	Calysta
422us110	US (Provisional)	Gas Fed Fermentation Reactors, Systems and Processes	Lapsed	17-Jun-2016	62/351,668	N/A	Calysta
422us210	US	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	15/625,858	US 2017/0362562	Calysta
422wo210	PCT	Gas Fed Fermentation Reactors, Systems and Processes	Nat'l Phase	16-Jun-2017	PCT/US2017/038008	WO 2017/218978	Calysta
422ae210	AE	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	P6001638/2018		Calysta
422au210	AU	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	2017286677		Calysta
422br210	BR	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	BR 11 2018 076053 6		Calysta
422ca210	CA	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	3,025,256		Calysta
422cn210	CN	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	201780037262.7	CN 109312281	Calysta
422ep210	EP	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	17734208.6		Calysta
422id210	ID	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	PID201810602		Calysta
422in210	IN	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	201817047952		Calysta
422jp210	JP	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	2018-565412		Calysta
422kr210	KR	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	10-2019-7000117		Calysta
422my210	MY	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	PI 2018002063		Calysta
422qa210	QA	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	QA/201812/00530		Calysta
422ru210	RU	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	2019100506		Calysta

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
422za210	ZA	Gas Fed Fermentation Reactors, Systems and Processes	Pending	16-Jun-2017	2018/07896		Calysta
426us110	US (Provisional)	Gas Fed Fermentation Reactors, Systems and Processes Utilizing a Vertical Flow Zone	Pending	10-Jan-2017	62/444,625	N/A	Calysta
426wo210	PCT	Gas Fed Fermentation Reactors, Systems and Processes Utilizing a Vertical Flow Zone	Pending	09-Jan-2018	PCT/US18/012965	WO 2018/132379	Calysta
427us110	US (Provisional)	Biological Production of Polyunsaturated Fatty Acids and Uses Thereof	Lapsed	30-Dec-2016	62/441,051	N/A	Calysta
427us210	US (Provisional)	Biological Production of Polyunsaturated Fatty Acids and Uses Thereof	Lapsed	29-Mar-2018	62/649,794	N/A	Calysta
428us110	US (Provisional)	Feed Compositions	Lapsed	16-Aug-2017	62/546,311	N/A	Calysta
428us210	US (Provisional)	Feed Compositions	Pending	16-Aug-2017	62/589,408	N/A	Calysta
428wo310	PCT	Feed Compositions	Pending	16-Aug-2017	PCT/US2018/000302	WO 2019/036017	Calysta
429us110	US (Provisional)	Reactor with Horizontal Gas Liquid Separator	Lapsed	14-Aug-2017	62/545,347	N/A	Calysta
429us210	US	Reactor with Horizontal Gas Liquid Separator	Pending	13-Aug-2018	16/102,448	US 2019/0048308	Calysta
429wo210	PCT	Reactor with Horizontal Gas Liquid Separator	Pending	13-Aug-2018	PCT/US2018/046518	WO 2019/0366372	Calysta
434us110	US (Provisional)	Materials, Devices and Methods for Removing Methane from a Gas Containing Methane	Pending	13-Aug-2018	62/679,492	N/A	Calysta
435us110	US (Provisional)	Glycogen-Null Methansotrophs and Uses Thereof	Pending	27-Dec-2018	62/785,668	N/A	Calysta
501uk110	UK (Priority)	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Lapsed	08-May-2009	0907963.3	N/A	Bioprotein
501uk210	UK (Priority)	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Lapsed	09-Nov-2009	0919586.8	N/A	Bioprotein
501c1310	CL	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Pending	10-May-2010	2011-2786	WO2010/128312	Bioprotein
501ep310	EP	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Granted	10-May-2010	10719037.3	EP 2 427 200 B1	Bioprotein
501es310	ES	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Granted	10-May-2010	10719037.3	EP 2 427 200 B1	Bioprotein
501fr310	FR	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Granted	10-May-2010	10719037.3	EP 2 427 200 B1	Bioprotein





Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
501gr310	GR	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Granted	10-May-2010	10719037.3	EP 2 427 200 B1	Bioprotein
501it310	IT	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Granted	10-May-2010	10719037.3	EP 2 427 200 B1	Bioprotein
501no310	NO	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Granted	10-May-2010	10719037.3	EP 2 427 200 B1	Bioprotein
501uk310	UK	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Granted	10-May-2010	10719037.3	EP 2 427 200 B1	Bioprotein
501wo310	PCT	Feed Composition for the Treatment or Prevention of Enteritis in Fish	Nat'l Phase	10-May-2010	PCT/GB2010/000946	WO2010/128312	Bioprotein
502uk110 (P4189UK)	UK	Method	Lapsed	16-Feb-2000	0003620.2	N/A	Bioprotein
502wo210 (P4189WO)	PCT	Method	Nat'l Phase	15-Feb-2001	PCT/GB01/00628	WO 01/60974	Bioprotein
502ep210 (P4189EP)	EP	Method for the Extraction of Proteins from a Single Cell	Granted	15-Feb-2001	EP01904208.4	EP 1 265 982 B1	Bioprotein
502cn210 (P4189CN)	CN	Method for the Extraction of Proteins from a Single Cell	Granted	15-Feb-2001	01805144.8	ZL 01805144.8	Bioprotein
502be210 (P4189BE)	BE	Method for the Extraction of Proteins from a Single Cell	Granted	15-Feb-2001	EP01904208.4	EP 1 265 982 B1	Bioprotein
502fr210 (P4189FR)	FR	Method for the Extraction of Proteins from a Single Cell	Granted	15-Feb-2001	EP01904208.4	EP 1 265 982 B1	Bioprotein
502nl210 (P4189NL)	NL	Method for the Extraction of Proteins from a Single Cell	Granted	15-Feb-2001	EP01904208.4	EP 1 265 982 B1	Bioprotein
502uk210 (P4189UK2)	UK	Method for the Extraction of Proteins from a Single Cell	Granted	15-Feb-2001	EP01904208.4	EP 1 265 982 B1	Bioprotein
503uk110 (P4334UK)	UK (Priority)	Method	Lapsed	12-Feb-2002	GB0203307.4	N/A	Bioprotein
503wo210 (P4334WO)	PCT	Bacterial Autolysate	Nat'l Phase	12-Feb-2003	PCT/GB03/00640	WO 03/068003	Bioprotein
503cn210 (P4334CN)	CN	Bacterial Autolysate	Granted	12-Feb-2003	03806228.3	ZL 03806228.3	Bioprotein
503no210 (P4334NO)	NO	Bacterial Autolysate	Granted	12-Feb-2003	20043789	335008 B1	Bioprotein
504uk110 (P4351-priority 1)	UK (Priority)	Method	Lapsed	16-Aug-2001	0120025.2	N/A	Bioprotein
504uk210 (P4351-priority 2)	UK (Priority)	Method	Lapsed	18-Apr-2002	0208906.8	N/A	Bioprotein
504au210 (P4351-3AU)	AU	Method of Fermentation	Granted	16-Aug-2002	2002355910	2002355910	Bioprotein







Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
504au220 (P4351-3AU2)	AU (DIV)	Method of Fermentation	Granted	16-Aug-2002	2006235784	2006235784	Bioprotein
504ca210 (P4351-3CA)	CA	Method of Fermentation	Granted	16-Aug-2002	2457225	2457225	Bioprotein
504cn210 (P4351-3CN)	CN	Method of Fermentation	Granted	16-Aug-2002	02819362.8	ZL 02819362.8	Bioprotein
504dk210 (P4351-3DK)	DK	Method of Fermentation	Granted	16-Aug-2002	02751442.1	EP 1 419 234 B1	Bioprotein
504ep210 (P4351-3EP)	EP	Method of Fermentation	Granted	16-Aug-2002	02751442.1	EP 1 419 234 B1	Bioprotein
504nl210 (P4351-3NL)	NL	Method of Fermentation	Granted	16-Aug-2002	02751442.1	EP 1 419 234 B1	Bioprotein
504no210 (P4351-3NO)	NO	Method of Fermentation	Granted	16-Aug-2002	20040693	332516	Bioprotein
504uk210 (P4351-3GB2)	UK	Method of Fermentation	Granted	16-Aug-2002	02751442.1	EP 1 419 234 B1	Bioprotein
504us210 (P4351-3US2)	US	Method of Fermentation	Granted	16-Aug-2002	10/486,694	7,579,163 (US 2004/0241790)	Bioprotein
504us220 (P4351-3US3)	US	Method of Fermentation	Lapsed	30-Jun-2009	12/495,320	US 2009/0263877	Bioprotein
504wo210 (P4351-3WO)	PCT	Method of Fermentation	Nat'l Phase	16-Aug-2002	PCT/GB02/03798	WO 2003/016460	Bioprotein
505uk110 (P4350UK)	UK (Priority)	Method	Lapsed	28-Feb-2002	0204722.3	N/A	Bioprotein
505wo210 (P4350WO)	PCT	Method	Nat'l Phase	31-May-2002	PCT/GB02/02555	WO 2003/072133	Bioprotein
505ep210 (P4350EP)	EP	Immunostimulatory Agent Comprising a Biomass of Methanotrophic Bacterium	Granted	31-May-2002	02727769.8	EP 1 478 376 B1	Bioprotein
505ca210 (P4350CA)	CA	Immunostimulatory Agent Comprising a Biomass of Methanotrophic Bacterium	Lapsed (Granted)	31-May-2002	PCT/GB02/02555	2477371	Bioprotein
505cn210 (P4350CN)	CN	Method	Lapsed	31-May-2002	02828389.9	1622815	Bioprotein
505no210 (P4350NO)	NO	Preparation and pharmaceutical compositions comprising a biomass accomplishments of a Microbial Culture Comprising Methylococcus capsulatus and uses thereof	Granted	31-May-2002	20043741	332176	Bioprotein
505us110 (P4350US)	US Provisional	Method	Lapsed	12-Mar-2002	60/363,092	N/A	Bioprotein
505us210 (P4350US2)	US	Method	Lapsed	31-May-2002	10/505,524	US 2005/0163802	Bioprotein
506uk110 (P4395GB1)	UK (Priority)	Product	Lapsed	19-Apr-2002	0209007.4	N/A	Bioprotein
506at210 (P4395AT)	AT	Growth Medium for Microorganisms Comprising the	Granted	17-Apr-2003	03746864.2	EP 1 497 409 B1	Bioprotein

Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
		Biomass of Methanotrophic and Heterotrophic Bacteria					
506ep210 (P4395EP)	EP	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	03746864.2	EP 1 497 409 B1	Bioprotein
506be210 (P4395BE)	BE	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	03746864.2	EP 1 497 409 B1	Bioprotein
506ca210 (P4395CA)	CA	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	PCT/GB03/01689	2481400	Bioprotein
506ch210 (P4395CH)	CH	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	03746864.2	EP 1 497 409 B1	Bioprotein
506de210 (P4395DE)	DE	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	03746864.2	60305476.5	Bioprotein
506dk210 (P4395DK)	DK	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	03746864.2	EP 1 497 409 B1	Bioprotein
506fr210 (P4395FR)	FR	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	03746864.2	EP 1 497 409 B1	Bioprotein
506in210 (P4395IN)	IN	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	3646/DELNP/2004	247677	Bioprotein
506kr210 (P4395KR)	KR	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	2004-7016808	10-0902396	Bioprotein
506nl210 (P4395NL)	NL	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	03746864.2	EP 1 497 409 B1	Bioprotein
506no210 (P4395NO)	NO	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	20045022	331278	Bioprotein
506sk210 (P4395SK)	SK	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	03746864.2	SK E 938 T3	Bioprotein
506uk210 (P4395GB2)	UK	Growth Medium for Microorganisms Comprising the	Granted	17-Apr-2003	03746864.2	EP 1 497 409 B1	Bioprotein


Docket No.	Country (Type)	Title	Status	Filing Date	Application No.	Issue / Publication No.	Assignee
		Biomass of Methanotrophic and Heterotrophic Bacteria					
506us110 (P4395US)	US (Provisional)	Method	Lapsed	31-May-2002	60/384,815	N/A	Bioprotein
506us210 (P4395US2)	US	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	17-Apr-2003	10/511,685	7,799,550	Bioprotein
506us220 (P4395US3)	US (DIV)	Growth Medium for Microorganisms Comprising the Biomass of Methanotrophic and Heterotrophic Bacteria	Granted	21-Jan-2009	12/357,240	8,592,198	Bioprotein
506wo210 (P4395WO)	PCT	Product	Nat'l Phase	17-Apr-2003	PCT/GB03/01689	WO03/089625	Bioprotein

EXHIBIT C

Country	Our Ref.	Mark	Classes	Appl. No.	Appl. Date	Reg. No.	Reg. Date	Owner
Chile	T2259020	FEEDKIND	01, 31	1.157.390	6/3/2015	1.187.599	11/30/2015	Calysta, Inc.
Czech Republic (Madrid)	T2259023	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263A	2/23/1998	690263A	2/23/1998	Calysta AS.
Denmark (Madrid)	T2259024	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263A	2/23/1998	690263A	2/23/1998	Calysta AS
European Union	T2259012	CALYSTA	01, 31, 40, 42	012714283	3/20/2014	012714283	8/14/2014	Calysta, Inc.
European Union	T2259013	CALYSTA	04, 05, 42	012714317	3/20/2014	012714317	8/14/2014	Calysta, Inc.
European Union	T2259019	FEEDKIND	01, 31	013964283	4/20/2015	013964283	8/24/2015	Calysta, Inc.
Finland (Madrid)	T2259025	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263	2/23/1998	690263	2/23/1998	Statoil ASA
France (Madrid)	T2259026	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263A	2/23/1998	690263A	2/23/1998	Calysta AS

Country	Our Ref.	Mark	Classes	Appl. No.	Appl. Date	Reg. No.	Reg. Date	Owner
Germany (Madrid)	T2259027	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263A	2/23/1998	690263A	2/23/1998	Calysta AS
Hungary (Madrid)	T2259028	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263	2/23/1998	690263	2/23/1998	Statoil ASA
Iceland (Madrid)	T2259029	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263	2/23/1998	690263	2/23/1998	Statoil ASA
International Protocol (Madrid)	T2259036	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263A	2/23/1998	690263A	2/23/1998	Calysta AS
International Protocol (Madrid)	T2259022	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263	2/23/1998	690263	2/23/1998	Statoil ASA
Norway	T2259021	 BioProtein BIOPROTEIN & Design	01, 29, 31	199801208	2/10/1998	191911	8/6/1998	Calysta AS
Norway	T2259015	CALYSTA	01, 04, 05, 31, 40, 42	201410203	9/4/2014	279589	12/22/2014	Calysta, Inc.

Country	Our Ref.	Mark	Classes	Appl. No.	Appl. Date	Reg. No.	Reg. Date	Owner
Norway	T2259018	FEEDKIND	01, 31	201506247	5/19/2015	283154	8/27/2015	Calysta, Inc.
Poland (Madrid)	T2259030	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263	2/23/1998	690263	2/23/1998	Statoil ASA
Portugal (Madrid)	T2259031	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263	2/23/1998	690263	2/23/1998	Statoil ASA
Singapore	T2259016	CALYSTA	01, 04, 05, 31, 40, 42	T1415981H	10/7/2014	T1415981 H	4/27/2015	Calysta, Inc.
Spain (Madrid)	T2259032	 BioProtein BIOPROTEIN & Design	01	690263	2/23/1998	690263	2/23/1998	Statoil ASA
Sweden (Madrid)	T2259033	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263	2/23/1998	690263	2/23/1998	Statoil ASA
Switzerland (Madrid)	T2259034	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263A	2/23/1998	690263A	2/23/1998	Calysta AS

Country	Our Ref.	Mark	Classes	Appl. No.	Appl. Date	Reg. No.	Reg. Date	Owner
United Kingdom (Madrid)	T2259035	 BioProtein BIOPROTEIN & Design	01, 29, 31	690263A	2/23/1998	690263A	2/23/1998	Calysta AS
United States	S2259002	BGTL	42	85/742,941	10/1/2012	4,412,415	10/1/2013	Calysta, Inc.
United States	S2259007	BIOGTC	42	85/777,420	11/12/2012	4,445,022	12/3/2013	Calysta, Inc.
United States	S2259003	BIOGTL	42	85/742,938	10/1/2012	4,412,414	10/1/2013	Calysta, Inc.
United States	S2259008	BIOLOGICAL GAS TO FEED	42	86/112,431	11/6/2013			Calysta, Inc.
United States	S2259040	BIOLOGICAL GAS TO FEED	42	87/314,271	1/26/2017			Calysta, Inc.
United States	S2259009	BIOLOGICAL GAS TO FUEL	42	86/112,432	11/6/2013			Calysta, Inc.
United States	S2259004	BIOLOGICAL GAS-TO-CHEMICALS	42	85/777,418	11/12/2012	4,416,218	10/8/2013	Calysta, Inc.

Country	Our Ref.	Mark	Classes	Appl. No.	Appl. Date	Reg. No.	Reg. Date	Owner
United States	S2259005	BIOLOGICAL GAS-TO-LIQUIDS	42	85/742,937	10/1/2012	4,412,413	10/1/2013	Calysta, Inc.
United States	S2259011	CALYSTA	01, 04, 05, 31, 40, 42	86/184,784	2/5/2014			Calysta, Inc.
United States	S2259006	CALYSTA ENERGY	42	85/742,936	10/1/2012	4,449,935	12/17/2013	Calysta, Inc.
United States	S2259017	FEEDKIND	01, 31	86/591,860	4/9/2015			Calysta, Inc.